Antibodies for
Immunohistochemistry
Parvovirus B19 (R92F6)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45250 IMPATH Parvovirus RTU M (R92F6)
50 Tests
44364 Parvovirus RTU M (R92F6)
7 ml Ready To Use
44748 Parvovirus 0,1 M (R92F6)
100 µl liquid Concentrated
44749 Parvovirus 1 M (R92F6)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Nuclear
Control
Parvovirus infected tissue
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-parvovirus targets the capsid proteins VP1 and VP2 on human parvovirus. Parvovirus B19 infection has been implicated as a cause in
spontaneous abortion in humans. Parvovirus B19 is also associated with erythema infectiosum (fifth disease) in children and acute arthritis in
adults, as well as chronic hemolytic anemia, with some patients experiencing aplastic crisis.
Reference
1. Loughrey AC, et al. J Med Vir. 1993; 39:97-100.
2. Moore L, et al. Med J Australia. 1993; 159:344-345.
3. Morey AL, et al. J Path. 1992; 166:105-108.
4. O’Neill HJ, et al. 1992; 123:125-134.
194
